China Market Research Reports adds “Research Report on China Human Vaccine Industry, 2011-2020” to its store.
Currently vaccination is one of the most effective approaches to prevent the spread of infectious diseases as well as one of the most cost-effective health intervention measures. Vaccination is helpful to trim down large amount of treatment expense. The research object of the report is human vaccine Industry apart from animal vaccine. Five pharmaceutical giants, MSD, Sanofi, Glaxo SmithKline, Pfizer and Novartis, take up significant share of the global market, with sales volume of over 80% globally. Yet in terms of vaccine output, these five giants totally produce less than 20% of the global output, meaning most of the vaccines are produced by manufacturers in the developing world. There are more than 30 vaccine manufacturing companies in China so far. They are capable of producing over 40 varieties of vaccines to prevent more than 20 infectious diseases. Compared with the international market, vaccine manufacturing companies in China have a larger total number yet a smaller individual scale.
Inquire for Discount @ http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=115336
In China, it is used to classifying vaccines into two catalogues: Vaccine I and Vaccine II. Vaccine I refers to those free vaccines provided by the government for the public, including vaccines against major epidemic diseases such as hepatitis B, epidemic meningitis and tetanus. Vaccines in this category are all priced by the government and purchased through bidding. Vaccine II mainly covers vaccines paid by citizens themselves. For Vaccine II, pricing falls into the hand of companies, thus offering a higher profit margin and yet forming a more fiercely competitive market. Some of the commonly used vaccines in the Vaccine II catalogue include Pneumonia Vaccine, Varicella Vaccine, Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine and Rabies Vaccine. In China, Vaccine I market is dominated by state-owned enterprises. Foreign and private enterprises gain certain advantages in the Vaccine II market. In China, as some problems still remain in the supervision and regulation in human vaccine industry, related accidents pop up constantly. This makes some Chinese residents tend to choose imported vaccines. The huge potential of China's human vaccine industry attracts international giants in vaccine industry to speed up their entry to Chinese market. In 2009 Novartis offered to purchase 85% shares of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. at USD 125 million. Such a bid was approved in March 2011. In June 2011, Glaxo SmithKline bought 51% shares of Neptunus Interlong held by Neptunus Pharmaceutical at GBP 24 million and set up a joint-venture subsidiary. In September 2011, Glaxo SmithKline signed with three new partners which were Sinopharm Group Co., Ltd., Shanghai Zuellig Pharmaceutical Co., Ltd. and Beijing Keyuan Xinhai Pharmaceutical Co., Ltd. The three distributors were respectively responsible for the distribution business in Northern, Central and Southern China. Through their cold chain logistics systems around the nation, they can provide services for clients in different parts of China.
Order a copy of Research Report on China Human Vaccine Industry, 2011-2020 @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=115336
Chart Introduction on Basic Ingredients of Vaccine
Chart Classification of Human Vaccines
Chart Comparison Between Traditional and New Vaccines
Chart Scale of the Global Vaccine Market, 2005-2015
Chart Introduction on Global Major Vaccines
Chart Major Varieties of Global Pneumonia Vaccine
Chart Major Hepatitis Vaccine in Global Market
More Reports of Life Sciences Industry @ http://www.chinamarketresearchreports.com/cat/life-sciences.html
China Market Research Reports
China market research reports portal aims at providing business intelligence, market research, company research, investment consultation and other market intelligence data for multiple industries in China. The reports available through our website are from publishers that focus on meeting research and information requirements of corporate, businesses, institutions, and global professional investors for IPO, corporate mergers and acquisition, business development, market launch, financing and more. These China reports are helpful for strategic formulation, forecasting, risk management, and investment research with all the available data and information analysis, saving time and money for businesses and clients. Feel free to get in touch with us ([email protected] / +1 888 391 5441) with your specific requirements, topics of interest or anything that you are not able to find on our portal.
P: + 1 888 391 5441